FDA drug approval acceleration policies continue under new commissioner

Regardless of Makary's tenure, FDA policies to speed up drug approvals and reduce regulatory burdens will persist through 2027. This reflects institutional momentum and bipartisan support for streamlining pharmaceutical innovation.

Implied probability (Yes)

75%